As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

Bulwark reporter Will Sommer reports MAGA influencer Laura Loomer is drawing criticism from MAGA members who claim she’s ...

Biogen touts “New Ventures” team; Why drug prices will remain high; San Diego biotech companies struggle to secure funding.

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...

President Trump's executive order to "identify and take appropriate action to correct past misconduct by the Federal Government related to censorship of protected speech" is good enough, DOJ tells ...

Janus Henderson reviews Q2 healthcare headwinds and standout biotech picks. Learn how the fund is navigating policy shifts ...

Vinay Prasad, a professor who until earlier this year headed a cancer-drugs and health-policy lab at UC San Francisco, ...

Vinay Prasad's interim replacement has concerns about same drug that drove him out. NIH director says employee critics ...

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.